LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
XAIR
Beyond Air, Inc.
There isn't enough reported data to score XAIR yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
XAIR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
XAIR's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
XAIR PE Valuation
XAIR has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
XAIR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect XAIR's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus XAIR down 150%.
XAIR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | -$424.00 | +$429.13 |
| Q3 2024 | -$564.00 | +$261.13 |
| Q2 2024 | -$656.00 | +$125.13 |
| Q1 2024 | -$728.00 | +$21.13 |
| Q4 2023 | -$853.13 | -$74.83 |
| Q3 2023 | -$825.13 | -$102.83 |
| Q2 2023 | -$781.13 | -$74.83 |
| Q1 2023 | -$749.13 | -$66.83 |
XAIR is still losing money, but far less than before: $424.00 per share over the past year, against $853.13 at its worst in late 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
XAIR has the stronger quarterly revenue trend. Revenue is up 39% for LLY versus up 145% for XAIR.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
XAIR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2025 | $1.2M | +145% |
| Q4 2024 | $1.1M | +174% |
| Q3 2024 | $798K | +234% |
| Q2 2024 | $683K | +1058% |
| Q4 2020 | $148.8K | -53% |
XAIR's revenue has grown year over year for six quarters in a row: $1M last quarter, up 145% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -623% | +2065 points |
| Q4 2024 | -1022% | +3317 points |
| Q3 2024 | -1608% | +5729 points |
| Q2 2024 | -1988% | +24919 points |
| Q1 2024 | -2688% | N/A |
| Q4 2023 | -4338% | N/A |
| Q3 2023 | -7337% | N/A |
| Q2 2023 | -26907% | N/A |
XAIR's operating margin was −623% last quarter, up 2065 points from the same quarter a year ago, near the top of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over XAIR on cash generation, producing positive trailing cash flow while its opponent burns cash.
XAIR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.3M | -$1.6M |
| Q2 2026 | -$5.2M | -$430K |
| Q1 2026 | -$5.5M | +$3M |
| Q4 2025 | -$4.3M | +$4M |
| Q3 2025 | -$4.7M | +$9.8M |
| Q2 2025 | -$4.7M | +$8.1M |
| Q1 2025 | -$8.5M | +$4.2M |
| Q4 2024 | -$8.3M | +$6.9M |
XAIR has burned cash in almost every quarter: −$21M over the past year, against −$26M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over XAIR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
XAIR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +188% | +1.4M shares |
| 1 year | +729% | +1.8M shares |
| 3 years | +2679% | +2M shares |
| 5 years | +4757% | +2M shares |
XAIR has 2M diluted shares, up 729% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
XAIR Net Leverage
XAIR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
XAIR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.2 | Oversold |
| Stochastic | 4.0 | Oversold |
XAIR's weekly RSI is 27 (oversold) and its Stochastic is 4 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
XAIR PE vs Healthcare Sector
XAIR has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over XAIR on trend strength, trading above more of its moving averages.
XAIR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.35 | 6% below |
| 20 week MA | $4.18 | 47% below |
| 50 week MA | $11.3 | 80% below |
| 100 week MA | $48.1 | 95% below |
| 200 week MA | $542.0 | 100% below |
XAIR is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over XAIR on returns for 2026, with the stronger performance.
XAIR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,752.0 | $2,084.0 | +19% |
| 2021 | $2,084.0 | $3,916.0 | +88% |
| 2022 | $3,916.0 | $2,496.0 | -36% |
| 2023 | $2,496.0 | $784.0 | -69% |
| 2024 | $784.0 | $176.0 | -78% |
| 2025 | $176.0 | $15.0 | -91% |
| 2026 YTD | $15.0 | $2.21 | -85% |
XAIR has finished four years in a row lower, and it's down 85% so far in 2026.